Marinus Pharmaceuticals Inc

$14.16 0.00% ($0.00)
  • 1D
  • 1W
  • 1M
  • 1Y
  • 5Y
  • YTD

Get ready to invest

Join the waitlist

About Marinus Pharmaceuticals Inc

Marinus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company focuses on developing and commercializing therapeutics to treat epilepsy and neuropsychiatric disorders. Its clinical-stage product candidate, ganaxolone, is a modulator being developed in various dose forms, including intravenous, oral capsule and oral liquid, intended to provide more treatment options to adult and pediatric patient populations in both acute and chronic care settings. Ganaxolone acts on the GABAA receptor, a target in the brain known for both anti seizure and anti anxiety effects through positive allosteric modulation. The Company is developing ganaxolone for multiple epilepsy and other neuropsychiatric indications, including adjunctive, or add-on, therapy for the treatment of drug-resistant focal onset seizures; status epilepticus; Fragile X Syndrome, and PCDH19 pediatric epilepsy.

Stock Analysis

last close $15.01
1-mo return -10.2%
3-mo return 20.6%
avg daily vol. 280.06T
52-week high 20.04
52-week low 6.04
market cap. $567M
forward pe -
annual div. -
roe -70.2%
ltg forecast -
dividend yield -
annual rev. $2M
inst own. 87.5%
baraka

Join the waitlist for early access and a chance to earn $50 in free stock

Join the waitlist